Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma
- PMID: 24569790
- DOI: 10.1038/ncomms4401
Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma
Abstract
We previously reported a disease segregating causal germline mutation in a melanoma family and recurrent somatic mutations in metastasized tumours from unrelated patients in the core promoter region of the telomerase reverse transcriptase (TERT) gene. Here we show that the TERT promoter mutations, besides causing an increased gene expression, associate with increased patient age, increased Breslow thickness and tumour ulceration in 287 primary melanomas. The mutations are more frequent at both intermittently and chronically sun-exposed sites than non-exposed sites and tend to co-occur with BRAF and CDKN2A alterations. The association with parameters generally connected with poor outcome, coupled with high recurrence and mechanistic relevance, raises the possibility of the eventual use of TERT promoter mutations in the disease management.
Comment in
-
Response.J Natl Cancer Inst. 2015 Mar 9;107(4):djv051. doi: 10.1093/jnci/djv051. Print 2015 Apr. J Natl Cancer Inst. 2015. PMID: 25755156 No abstract available.
Similar articles
-
Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.Virchows Arch. 2015 Aug;467(2):177-84. doi: 10.1007/s00428-015-1784-x. Epub 2015 Jun 9. Virchows Arch. 2015. PMID: 26055532
-
TERT promoter mutation is uncommon in acral lentiginous melanoma.J Cutan Pathol. 2014 Jun;41(6):504-8. doi: 10.1111/cup.12323. Epub 2014 Apr 2. J Cutan Pathol. 2014. PMID: 24588324
-
TERT promoter mutations in familial and sporadic melanoma.Science. 2013 Feb 22;339(6122):959-61. doi: 10.1126/science.1230062. Epub 2013 Jan 24. Science. 2013. PMID: 23348503
-
TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.J Cutan Pathol. 2020 Aug;47(8):710-719. doi: 10.1111/cup.13691. Epub 2020 Apr 3. J Cutan Pathol. 2020. PMID: 32202662 Review.
-
TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.Crit Rev Oncol Hematol. 2021 Apr;160:103288. doi: 10.1016/j.critrevonc.2021.103288. Epub 2021 Mar 3. Crit Rev Oncol Hematol. 2021. PMID: 33675908 Review.
Cited by
-
Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.Dermatopathology (Basel). 2024 Jan 18;11(1):26-51. doi: 10.3390/dermatopathology11010005. Dermatopathology (Basel). 2024. PMID: 38247727 Free PMC article. Review.
-
Factors Affecting Recurrence and Survival for Patients with High-Risk Stage II Melanoma.Ann Surg Oncol. 2024 Apr;31(4):2713-2726. doi: 10.1245/s10434-023-14724-5. Epub 2023 Dec 29. Ann Surg Oncol. 2024. PMID: 38158497 Free PMC article.
-
pTERT C250T mutation: A potential biomarker of poor prognosis in metastatic melanoma.Heliyon. 2023 Aug 6;9(8):e18953. doi: 10.1016/j.heliyon.2023.e18953. eCollection 2023 Aug. Heliyon. 2023. PMID: 37609429 Free PMC article.
-
TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.Oncologist. 2024 Jan 5;29(1):8-14. doi: 10.1093/oncolo/oyad208. Oncologist. 2024. PMID: 37462445 Free PMC article.
-
TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.PLoS One. 2023 Jul 7;18(7):e0281487. doi: 10.1371/journal.pone.0281487. eCollection 2023. PLoS One. 2023. PMID: 37418389 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
